P2X7 Receptors: a Bibliometric Review from 2002 to 2023

Overview

Journal Purinergic Signal

Publisher Springer

Date 2024 Feb 29

PMID 38421486

Authors

Haiting Tang

Wei Wei

Yu Luo

Xiaoqing Lu

Jun Chen

Shenqiao Yang

Fei Wu

Haiyan Zhou

Wenbin Ma

Xin Yang

Affiliations

Soon will be listed here.

Abstract

For many years, there has been ongoing research on the P2X7 receptor (P2X7R). A comprehensive, systematic, and objective evaluation of the scientific output and status of P2X7R will be instrumental in guiding future research directions. This study aims to present the status and trends of P2X7R research from 2002 to 2023. Publications related to P2X7R were retrieved from the Web of Science Core Collection database. Quantitative analysis and visualization tools were Microsoft Excel, VOSviewer, and CiteSpace software. The analysis content included publication trends, literature co-citation, and keywords. 3282 records were included in total, with the majority of papers published within the last 10 years. Based on literature co-citation and keyword analysis, neuroinflammation, neuropathic pain, gastrointestinal diseases, tumor microenvironment, rheumatoid arthritis, age-related macular degeneration, and P2X7R antagonists were considered to be the hotspots and frontiers of P2X7R research. Researchers will get a more intuitive understanding of the status and trends of P2X7R research from this study.

References

Di Virgilio F, Dal Ben D, Sarti A, Giuliani A, Falzoni S . The P2X7 Receptor in Infection and Inflammation. Immunity. 2017; 47(1):15-31. DOI: 10.1016/j.immuni.2017.06.020. View

Burnstock G, Knight G . The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression. Purinergic Signal. 2017; 14(1):1-18. PMC: 5842154. DOI: 10.1007/s11302-017-9593-0. View

Csoka B, Nemeth Z, Toro G, Idzko M, Zech A, Koscso B . Extracellular ATP protects against sepsis through macrophage P2X7 purinergic receptors by enhancing intracellular bacterial killing. FASEB J. 2015; 29(9):3626-37. PMC: 4550379. DOI: 10.1096/fj.15-272450. View

Song X, Xu X, Zhu J, Guo Z, Li J, He C . Up-regulation of P2X7 receptors mediating proliferation of Schwann cells after sciatic nerve injury. Purinergic Signal. 2015; 11(2):203-13. PMC: 4425717. DOI: 10.1007/s11302-015-9445-8. View

Evangelinellis M, Souza R, Mendes C, Castelucci P . Effects of a P2X7 receptor antagonist on myenteric neurons in the distal colon of an experimental rat model of ulcerative colitis. Histochem Cell Biol. 2021; 157(1):65-81. DOI: 10.1007/s00418-021-02039-z. View

Machado F, Souza R, Figliuolo V, Coutinho-Silva R, Castelucci P . Effects of experimental ulcerative colitis on myenteric neurons in P2X7-knockout mice. Histochem Cell Biol. 2023; 160(4):321-339. DOI: 10.1007/s00418-023-02208-2. View

Magalhaes H, Machado F, Souza R, Caetano M, Figliuolo V, Coutinho-Silva R . Study of the roles of caspase-3 and nuclear factor kappa B in myenteric neurons in a P2X7 receptor knockout mouse model of ulcerative colitis. World J Gastroenterol. 2023; 29(22):3440-3468. PMC: 10303518. DOI: 10.3748/wjg.v29.i22.3440. View

Hattori M, Gouaux E . Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature. 2012; 485(7397):207-12. PMC: 3391165. DOI: 10.1038/nature11010. View

10.

Wiley J, Sluyter R, Gu B, Stokes L, Fuller S . The human P2X7 receptor and its role in innate immunity. Tissue Antigens. 2011; 78(5):321-32. DOI: 10.1111/j.1399-0039.2011.01780.x. View

11.

Zhang W, Zhu Z, Liu Z . The role and pharmacological properties of the P2X7 receptor in neuropathic pain. Brain Res Bull. 2019; 155:19-28. DOI: 10.1016/j.brainresbull.2019.11.006. View

12.

Gutierrez-Martin Y, Bustillo D, Gomez-Villafuertes R, Sanchez-Nogueiro J, Torregrosa-Hetland C, Binz T . P2X7 receptors trigger ATP exocytosis and modify secretory vesicle dynamics in neuroblastoma cells. J Biol Chem. 2011; 286(13):11370-81. PMC: 3064193. DOI: 10.1074/jbc.M110.139410. View

13.

Jiang L, Caseley E, Muench S, Roger S . Structural basis for the functional properties of the P2X7 receptor for extracellular ATP. Purinergic Signal. 2021; 17(3):331-344. PMC: 8410900. DOI: 10.1007/s11302-021-09790-x. View

14.

Burnstock G, Jacobson K, Christofi F . Purinergic drug targets for gastrointestinal disorders. Curr Opin Pharmacol. 2017; 37:131-141. PMC: 5859324. DOI: 10.1016/j.coph.2017.10.011. View

15.

Shokoples B, Paradis P, Schiffrin E . P2X7 Receptors: An Untapped Target for the Management of Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2020; 41(1):186-199. PMC: 7752223. DOI: 10.1161/ATVBAHA.120.315116. View

16.

Zhao M, Gu H, Pan W, Liu P, Zhu T, Shang H . SynCAM1 deficiency in the hippocampal parvalbumin interneurons contributes to sevoflurane-induced cognitive impairment in neonatal rats. CNS Neurosci Ther. 2023; 30(1):e14554. PMC: 10805405. DOI: 10.1111/cns.14554. View

17.

Skaper S, Debetto P, Giusti P . The P2X7 purinergic receptor: from physiology to neurological disorders. FASEB J. 2009; 24(2):337-45. DOI: 10.1096/fj.09-138883. View

18.

Adinolfi E, Giuliani A, De Marchi E, Pegoraro A, Orioli E, Di Virgilio F . The P2X7 receptor: A main player in inflammation. Biochem Pharmacol. 2017; 151:234-244. DOI: 10.1016/j.bcp.2017.12.021. View

19.

Sperlagh B, Illes P . P2X7 receptor: an emerging target in central nervous system diseases. Trends Pharmacol Sci. 2014; 35(10):537-47. DOI: 10.1016/j.tips.2014.08.002. View

20.

Di Virgilio F, Sarti A, Falzoni S, De Marchi E, Adinolfi E . Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat Rev Cancer. 2018; 18(10):601-618. DOI: 10.1038/s41568-018-0037-0. View

21.

Bartlett R, Stokes L, Sluyter R . The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease. Pharmacol Rev. 2014; 66(3):638-75. DOI: 10.1124/pr.113.008003. View